Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Verastem, Inc. clinical trials
The registry lists 27 studies whose lead sponsor is Verastem, Inc.. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Verastem, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Verastem, Inc..
- Verastem, Inc.27 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 27 of 27.
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingNCT07020221Phase 1/2
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerRecruitingNCT07659782Phase 2
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerRecruitingNCT07644559Phase 2
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerRecruitingNCT07659795Phase 2
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT06072781Phase 3
- Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)Not yet recruitingNCT07747506Phase 2
- Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsCompletedNCT05375994Phase 1/2
- Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingNCT05074810Phase 1/2
- A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsActive, not recruitingNCT06682572Phase 2
- Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerActive, not recruitingNCT05669482Phase 1/2
- A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS MutationActive, not recruitingNCT04625270Phase 2
- Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsTerminatedNCT02004028Phase 2
- A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerCompletedNCT04620330Phase 2
- Food Effect of VS-6766 in Healthy Adult SubjectsCompletedNCT05187169Phase 1
- Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian CancerTerminatedNCT02943317Phase 1
- Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic MalignanciesTerminatedNCT01849744Phase 1
- Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer SubjectsTerminatedNCT02651727Phase 1
- Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian CancerCompletedNCT01778803Phase 1
- Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung CancerCompletedNCT01951690Phase 2
- Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic MalignanciesCompletedNCT01943292Phase 1
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant MesotheliomaTerminatedNCT02372227Phase 1
- A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male SubjectsCompletedNCT02913716Phase 1
- Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural MesotheliomaTerminatedNCT01870609Phase 2
- Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT02215629Phase 1
- Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or LymphomaTerminatedNCT01991938Phase 1
- A Study Of PF-04554878 In Patients With Advanced Non-Hematologic MalignanciesCompletedNCT00787033Phase 1
- Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic NeoplasmsCompletedNCT00666926Phase 1